Fennec Pharmaceuticals Stock (NASDAQ:FENC)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$10.32

52W Range

$5.65 - $13.25

50D Avg

$11.05

200D Avg

$9.13

Market Cap

$353.48M

Avg Vol (3M)

$185.59K

Beta

1.10

Div Yield

-

FENC Company Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

35

IPO Date

Sep 15, 2017

Website

FENC Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 20
Royalty	$170.00K

Fiscal year ends in Dec 25 | Currency in USD

FENC Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$45.42M	$47.54M	$21.25M
Operating Income	$-6.86M	$2.57M	$-12.77M
Net Income	$-10.27M	$-436.00K	$-16.05M
EBITDA	$-6.86M	$4.80M	$-12.36M
Basic EPS	$-0.36	$-0.02	$-0.60
Diluted EPS	$-0.36	$-0.02	$-0.60

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 11, 26 | 8:30 AM

Q1 26May 14, 26 | 8:30 AM

Q4 25Mar 24, 26 | 8:30 AM

Peer Comparison

Ticker	Company
RNAC	Cartesian Therapeutics, Inc.
EPRX	Eupraxia Pharmaceuticals Inc.
AARD	Aardvark Therapeutics, Inc. Common Stock
AVTX	Avalo Therapeutics, Inc.
OBIO	Orchestra BioMed Holdings, Inc.
CRBU	Caribou Biosciences, Inc.
ENTA	Enanta Pharmaceuticals, Inc.
PRLD	Prelude Therapeutics Incorporated
BDTX	Black Diamond Therapeutics, Inc.
NAUT	Nautilus Biotechnolgy, Inc.